Hisun Pharmaceutical Submitted For Sirolimus To China FDA
This article was originally published in PharmAsia News
Executive Summary
China FDA has accepted the application Zhejiang Hisun Pharmaceutical Co. Ltd. for a Class 3.1 drug, sirolimus, as both a chemical API drug and an injectable drug.